

**DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR OEDEMA
SECONDARY TO RETINAL VEIN OCCLUSION**
RECOMMENDED ONLY IN LINE WITH THE CRITERIA GIVEN

Name: generic (trade)	What it is	Indication	Date Decision last revised	Decision Status	NICE / SMC Guidance
Dexamethasone intravitreal implant (Ozurdex®)	Corticosteroid	Treatment of adult patients with macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)	August 2011	Final	NICE – TA229, recommended

HMMC Recommendation, following further clarification of NICE TAG229 with specialists:
RECOMMENDED FOR RESTRICTED USE in line with NICE criteria.

Initiation Criteria

- Patient is over 18 years of age.
- Treatment should be in the worse-seeing eye only, unless patient is registered blind in one eye.
- Visual acuity in the eye to be treated is between 6/12 and 6/96.
- Further initiation criteria are as follows:

BRVO	CRVO
OCT ≥250 microns and haemorrhages are not masking fovea and no macular ischaemia on FFA. Laser coagulation has been tried and was unsuccessful, or the extent of the disease makes laser photocoagulation unsuitable.	OCT ≥250 microns and no macular ischaemia present on FFA.

Re-treatment Criteria

Re-treatment of an eye previously treated with dexamethasone is only recommended:

- At an injection interval of >6 months.
- Where the treated eye showed an initial response to dexamethasone, assessed at day 60 after treatment, with best corrected visual acuity (BCVA) improvement of >15 letters, but has since deteriorated by >5 letters.
- For a maximum of 6 doses.

Further Criteria

- In line with the activity costs included in the economic evaluation which informed the NICE TA recommendation, commissioners would only expect to pay a day case tariff in 2012/13. From 2013/14 onwards, an outpatient activity tariff only will be paid. Any charges above this will require local contract negotiation.
- BCVA must be documented when treatment is given, 60 days after treatment and when treatment is repeated.

NICE criteria

- Dexamethasone intravitreal implant is recommended **as an option** for the treatment of macular oedema following central retinal vein occlusion (CRVO).
- Dexamethasone intravitreal implant is recommended **as an option** for the treatment of macular oedema following branch retinal vein occlusion (BRVO) when:
 - treatment with laser photocoagulation has not been beneficial, or
 - treatment with laser photocoagulation is not considered suitable because of the extent of macular haemorrhage.

Reference: NICE TAG 229 -Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion, August 2011 <http://guidance.nice.org.uk/TA229>